Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

View:
Post by Mole101 on Aug 17, 2021 5:01pm

HALT !!!

Mmmmmm....$$$?
Comment by farmerjane on Aug 17, 2021 5:06pm
$ 15 million US, for the insiders and the Boston Family. Clear why no information was forth coming. The Immusafe unlock was probably just a distraction and means nothing, i believe management was not interested in making a deal with Pharma.
Comment by Mole101 on Aug 17, 2021 5:07pm
TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ ProMIS ” or the “ Company ”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has filed today a preliminary prospectus supplement (the “ Supplement ”) to its ...more  
Comment by Annayya on Aug 17, 2021 5:16pm
$15 million. Thats probably be the biggest amount ever being rsised by PMN in a single financing. It doesn't say the price of each share they are selling at, and they also halted trading. This is hopefully setting up for news or something to push the SP higer.
Comment by Annayya on Aug 17, 2021 5:21pm
$15 million USD = $19 million CAD Glad to see some serious progression on starting PMN310 Phase 1 clinicals
Comment by Gbathat on Aug 17, 2021 7:03pm
 $15M would be enough to cover Pre-clincal development for Ph1 for PMN310.  But I thought the latest documents filed by the company indicated that they would not apply for Ph1 consideration until the end of 2022. from the Aug 12 MD&A ------------------ Should further capital be available on a timely basis, ProMIS estimates it will be able to complete in Q4, 2022, the pre-clinical ...more  
Comment by Annayya on Aug 17, 2021 7:26pm
For once could it be possible that they are moving the timelines ahead for a change. I really hope so.
Comment by M101 on Aug 17, 2021 5:40pm
Darn, I was wrong, news before Labour Day.  Oh well, I guess that's why I've just been holding for years. But yippeee, it's not another Goldstein deal.   
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities